Johnson & Johnson spinout PrEP Biopharm has announced that former GSK Global Head of Analytical Technologies Anna Slater has joined the company as Head of Chemistry, Manufacturing and Controls. At GSK, Slater had been a Senior Director in the global Inhaled Product & Device Technology Leadership Team, responsible for CMC development of inhaled and nasal products and was most recently the CMC lead for Arnuity Ellipta and for vilanterol monotherapy. The company also announce the hire of Mike McGuiness, most recently COO of Proception Medical, as Chief Financial Officer.
PrEP Biopharm’s lead product is PrEP-001 an intranasal “broad-spectrum agent that leverages the innate immune system to prevent upper respiratory tract viral infections (colds and flus).” The technology is licensed from J&J subsidiary Janssen Sciences Ireland.
Slater commented, “Most of my career has focused on the strategic and technical CMC aspects of drug development for respiratory diseases. I hope my experience will help accelerate the development of PrEP-001 and I’m really pleased to be joining the team at a very dynamic time for PrEP Biopharm.”
PrEP CEO Ryan Muldoon said, “I’m incredibly excited to have Mike and Anna join the PrEP Leadership Team. They each have a tremendous track record of success in efficiently bringing new drugs to market. Their experience and insights will have an immediate impact as we move PrEP-001 through Phase 2 and plan for future development.”
Read the PrEP Biopharm press release.
